Comparison
BPC-157 vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
204656-20-2
Molecular weight
1419.5 g/mol
3751 g/mol
Half-life
4 h
13 h
Sequence
GEPPPGKPADDAGLVHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
5
of which in humans
0
4
Effects recorded
4
3
Open conflicts
2
0
Documented adverse events
2
1